Expertise in
8
conditions

Olivier Vittecoq

Rouen, FR 
Expertise in
8
conditions
Rouen, FR 

Overview

Olivier Vittecoq practices practicing medicine in Rouen, France.

Mr. Vittecoq is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Rheumatoid Arthritis (RA), Arthritis, Sjogren Syndrome, and Dry Mouth.

He is actively involved in clinical research, co-authoring 124 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

Rouen, 76000, France
Other Locations
CHU of Nîmes
Nimes, France
CHU of Strasbourg
Strasbourg, 68000, France
Nantes, 44093, France
Lille, France
Bois-la-ville, France
Boulevard Tanguy Prigent
Brest, 29609, France
CHU Bravois
Vandoeuvre-les-nancy, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Interest of Continuous Non-Steroidal Anti-Inflammatory Drug Treatment in Ankylosing Spondylitis Patients Treated by Anti-TNF Therapy in the Prevention of Radiographic Outcomes
Interest of Continuous Non-Steroidal Anti-Inflammatory Drug Treatment in Ankylosing Spondylitis Patients Treated by Anti-TNF Therapy in the Prevention of Radiographic Outcomes
Enrollment Status: Completed
Publish Date: May 19, 2026
Intervention Type: Drug
Study Drugs: NSAIDs, anti-TNF
Study Phase: Phase 3
Efficiency of a Tight Monitoring by a Nurse Practitioner of Rheumatoid Arthritis (RA) Patients in Remission (or Low Disease Activity) Under Rituximab to Detect Early Relapse of the Disease
Efficiency of a Tight Monitoring by a Nurse Practitioner of Rheumatoid Arthritis (RA) Patients in Remission (or Low Disease Activity) Under Rituximab to Detect Early Relapse of the Disease
Enrollment Status: Completed
Publish Date: April 16, 2026
Intervention Type: Other
Study Phase: Not Applicable
Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis
Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: January 20, 2026
Intervention Type: Drug
Study Phase: Phase 4
Prediction of Abatacept Discontinuation Using Test Reflecting Immunological Remission in Rheumatoid Arthritis
Prediction of Abatacept Discontinuation Using Test Reflecting Immunological Remission in Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: March 06, 2025
Lead Time of the Methotrexate Establishment and Vaccinal Protection Against the Pneumococcal Agent in Patients Affected With Rheumatoid Polyarthritis
Lead Time of the Methotrexate Establishment and Vaccinal Protection Against the Pneumococcal Agent in Patients Affected With Rheumatoid Polyarthritis
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
Comparative Analysis of Two Therapeutic Strategies: Early Switch Versus Therapeutic Intensification in Patients With Spondyloarthritis Treated With Anti-tnf Biologics, in Case of Secondary Treatment Failure Suspicion.
Comparative Analysis of Two Therapeutic Strategies: Early Switch Versus Therapeutic Intensification in Patients With Spondyloarthritis Treated With Anti-tnf Biologics, in Case of Secondary Treatment Failure Suspicion.
Enrollment Status: Terminated
Publish Date: June 15, 2017
Intervention Type: Biological
Study Phase: Phase 4
View 5 Less Clinical Trials

124 Total Publications

Anti-carbamylated fibrinogen autoantibodies of IgG and IgA isotypes contribute to a better prognostic stratification in very early rheumatoid arthritis: data from the French national ESPOIR cohort.
Anti-carbamylated fibrinogen autoantibodies of IgG and IgA isotypes contribute to a better prognostic stratification in very early rheumatoid arthritis: data from the French national ESPOIR cohort.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: March 26, 2026

Frequently Asked Questions about Olivier Vittecoq

Is Olivier Vittecoq a top-rated expert for Rheumatoid Arthritis (RA)?

MediFind is an objective health platform that identifies experts based on real-world data. Olivier Vittecoq is classified as an Elite expert for Rheumatoid Arthritis (RA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Olivier Vittecoq participate in research or clinical trials?

Yes. Olivier Vittecoq has published 124 articles and abstracts on conditions like Rheumatoid Arthritis (RA). You can view a list of Olivier Vittecoq's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Vittecoq's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile